Third Rock Ventures IV, L.P. - Feb 7, 2023 Form 4 Insider Report for Magenta Therapeutics, Inc. (MGTA)

Role
10%+ Owner
Signature
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P.
Stock symbol
MGTA
Transactions as of
Feb 7, 2023
Transactions value $
-$3,056,000
Form type
4
Date filed
2/9/2023, 03:30 PM
Previous filing
Aug 26, 2021
Next filing
Feb 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGTA Common Stock Sale -$1.83M -2.2M -32.55% $0.83 4.56M Feb 7, 2023 Direct F1, F2
transaction MGTA Common Stock Sale -$1.23M -1.5M -32.91% $0.82 3.06M Feb 8, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Third Rock Ventures IV, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.808 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2 These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.801 to $0.893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).